Transgenic models for cytokine-induced neurological disease

Biochimica et Biophysica Acta - Molecular Basis of Disease

Volumn 1802, Issue 10, 2010, Pages 903-917

  Campbell, Iain L ^a   Hofer, Markus J ^b   Pagenstecher, Axel ^b  

^a UNIVERSITY OF SYDNEY   (Australia)

^b PHILIPPS UNIVERSITY MARBURG   (Germany)

Author keywords

Central nervous system; Cytokine; Interferon; Interleukin 12; Interleukin 6; Neurological disease; Transforming growth factor beta; Transgenic mouse

Indexed keywords

ALPHA INTERFERON; CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 12; INTERLEUKIN 12P35; INTERLEUKIN 12P40; INTERLEUKIN 6; MESSENGER RNA; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ANTIVIRAL ACTIVITY; B LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CENTRAL NERVOUS SYSTEM; CYTOKINE PRODUCTION; DEMYELINATING DISEASE; DISEASE MODEL; ENCEPHALITIS; GENE EXPRESSION; HUMAN; IMMUNOPATHOGENESIS; IMMUNOSTIMULATION; MENINGITIS; MENINGOENCEPHALOMYELITIS; MOUSE; MYELITIS; NERVE CELL LESION; NERVOUS SYSTEM INFLAMMATION; NEUROLOGIC DISEASE; NONHUMAN; PHENOTYPIC VARIATION; PRIORITY JOURNAL; REVIEW; TRANSGENIC MOUSE; ANIMAL; METABOLISM;

ANIMALS; CYTOKINES; DISEASE MODELS, ANIMAL; HUMANS; MICE; MICE, TRANSGENIC; NERVOUS SYSTEM DISEASES;

ANIMALIA; MUS; MUS MUSCULUS;

EID: 77956094385     PISSN: 09254439     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbadis.2009.10.004     Document Type: Review

References (186)

1. John G.R., Lee S.C., Brosnan C.F. Cytokines: powerful regulators of glial cell activation. Neuroscientist 2003, 9:10-22.
2. Rothwell N.J., Hopkins S.J. Cytokines and the nervous system: II. Actions and mechanisms of action. Trends Neurosci. 1995, 18:130-136.
3. Hopkins S.J., Rothwell N.J. Cytokines and the nervous system: 1. Expression and recognition. Trends Neurosci. 1995, 18:83-88.
4. Steinman L. Nuanced roles of cytokines in three major human brain disorders. J. Clin. Invest. 2008, 118:3557-3563.
5. Taga T., Kishimoto T. Gp130 and the interleukin-6 family of cytokines. Annu. Rev. Immunol. 1997, 15:797-819.
6. Bauer S., Kerr B.J., Patterson P.H. The neuropoietic cytokine family in development, plasticity, disease and injury. Nat. Rev., Neurosci. 2007, 8:221-232.
7. Hirano T., Akira S., Taga T., Kishimoto T. Biological and clinical aspects of interleukin 6. Immunol. Today 1990, 11:443-449.
8. Ernst M., Jenkins B.J. Acquiring signalling specificity from the cytokine receptor gp130. Trends Genet. 2004, 20:23-32.
9. Heinrich P.C., Behrmann I., Haan S., Hermanns H.M., Muller-Newen G., Schaper F. Principles of interleukin (IL)-6-type cytokine signalling and its regulation. Biochem. J. 2003, 374:1-20.
10. Eskandari F., Sternberg E.M. Neural-immune interactions in health and disease. Ann. N.Y. Acad. Sci. 2002, 966:20-27.
11. Gadient R.A., Otten U.H. Interleukin-6 (IL-6)-a molecule with both beneficial and destructive potentials. Prog. Neurobiol. 1997, 52:379-390.
12. Gruol D.L., Nelson T.E. Physiological and pathological roles of interleukin-6 in the central nervous system. Mol. Neurobiol. 1997, 15:307-339.
13. Campbell I.L., Abraham C.R., Masliah E., Kemper P., Inglis J.D., Oldstone M.B.A., Mucke L. Neurologic disease induced in transgenic mice by the cerebral overexpression of interleukin 6. Proc. Natl. Acad. Sci. U. S. A. 1993, 90:10061-10065.
14. Campbell I.L. Structural and functional impact of the transgenic expression of cytokines in the CNS. Ann. N.Y. Acad. Sci. 1998, 840:83-96.
15. Heyser C.J., Masliah E., Samimi A., Campbell I.L., Gold L.H. Progressive decline in avoidance learning paralleled by inflammatory neurodegeneration in transgenic mice expressing interleukin 6 in the brain. Proc. Natl. Acad. Sci. U. S. A. 1997, 94:1500-1505.
16. Weaver J., Seeman T. Interleukin-6 as a predictor of cognitive function and cognitive decline. J. Am. Geriatr. Soc. 2000, 48:S2-S8.
17. Sternberg E.M. Neural-immune interactions in health and disease. J. Clin. Invest. 1997, 100:2641-2647.
18. Raber J., O'Shea R.D., Bloom F.E., Campbell I.L. Modulation of hypothalamic-pituitary-adrenal function by transgenic expression of interleukin-6 in the CNS of mice. J. Neurosci. 1997, 17:9473-9480.
19. Mastorakos G., Chrousos G.P., Weber J.S. Recombinant interleukin-6 activates the hypothalamic-pituitary-adrenal axis in humans. J. Clin. Endocrinol. Metab. 1993, 77:1690-1694.
20. Gold P.W., Licinio J., Wong M.L., Chrousos G.P. Corticotropin releasing hormone in the pathophysiology of melancholic and atypical depression and in the mechanism of action of antidepressant drugs. Ann. N.Y. Acad. Sci. 1995, 771:716-729.
21. Hatzinger M., Z'Brun A., Hemmeter U., Seifritz E., Baumann F., Holsboer-Trachsler E., Heuser I.J. Hypothalamic-pituitary-adrenal system function in patients with Alzheimer's disease. Neurobiol. Aging 1995, 16:205-209.
22. Aguilera G. Regulation of pituitary ACTH secretion during chronic stress. Front. Neuroendocrinol. 1994, 15:321-350.
23. Samland H., Huitron-Resendiz S., Masliah E., Criado J., Henriksen S.J., Campbell I.L. Profound increase in sensitivity to glutamatergic-but not cholinergic agonist-induced seizures in transgenic mice with astrocyte production of IL-6. J. Neurosci. Res. 2003, 73:176-187.
24. Steffensen S.C., Campbell I.L., Henriksen S.J. Site-specific hippocampal pathophysiology due to cerebral overexpression of interleukin-6 in transgenic mice. Brain Res. 1994, 652:149-153.
25. Bellinger F.P., Madamba S.G., Campbell I.L., Siggins G. Reduced long-term potentiation in the dentate gyrus of transgenic mice with cerebral overexpression of interleukin-6. Neurosci. Lett. 1995, 198:95-98.
26. Celio M.R. Parvalbumin in most g-aminobutyric acid-containing neurons of the rat cerebral cortex. Science 1986, 231:995-997.
27. Powell H.C., Campbell I.L. Ultrastructural abnormalities of glia and the blood brain barrier in a transgenic mouse overexpressing interleukin-6. Brain Pathol. 1994, 4:278.
28. Nishimoto N. Cytokine signal regulation and autoimmune disorders. Autoimmunity 2005, 38:359-367.
29. Chiang C.-S., Stalder A., Samimi A., Campbell I.L. Reactive gliosis as a consequence of interleukin-6 expression in the brain. Studies in transgenic mice. Dev. Neurosci. 1994, 16:212-221.
30. Barnum S.R., Jones J.L., Muller-Ladner U., Samimi A., Campbell I.L. Chronic complement C3 gene expression in the CNS of transgenic mice with astrocyte-targeted interleukin-6 expression. Glia 1996, 18:107-117.
31. Carrasco J., Hernandez J., Campbell I.L., Hidalgo J. Localization of metallothionein-I and -III expression in the CNS of transgenic mice with astrocyte-targeted expression of interleukin-6. Exp. Neurol. 1998, 153:184-194.
32. Brett F.M., Mizisin A.P., Powell H.C., Campbell I.L. Evolution of neuropathologic abnormalities associated with blood-brain barrier breakdown in transgenic mice expressing interleukin-6 in astrocytes. J. Neuropathol. Exp. Neurol. 1995, 54:766-775.
33. Milner R., Campbell I.L. Increased expression of the beta4 and alpha5 integrin subunits in cerebral blood vessels of transgenic mice chronically producing the pro-inflammatory cytokines IL-6 or IFN-alpha in the central nervous system. Mol. Cell. Neurosci. 2006, 33:429-440.
34. Sanz E., Hofer M.J., Unzeta M., Campbell I.L. Minimal role for STAT1 in interleukin-6 signaling and actions in the murine brain. Glia 2007, 56:190-199.
35. Penkowa M., Giralt M., Lago N., Camats J., Carrasco J., Hernandez J., Molinero A., Campbell I.L., Hidalgo J. Astrocyte-targeted expression of IL-6 protects the CNS against a focal brain injury. Exp. Neurol. 2003, 181:130-148.
36. Quintana A., Molinero A., Borup R., Nielsen F.C., Campbell I.L., Penkowa M., Hidalgo J. Effect of astrocyte-targeted production of IL-6 on traumatic brain injury and its impact on the cortical transcriptome. Dev. Neurobiol. 2008, 68:195-208.
37. Swartz K.R., Liu F., Sewell D., Schochet T., Campbell I.L., Sandor M., Fabry Z. Interleukin-6 promotes post-traumatic healing in the central nervous system. Brain Res. 2001, 896:86-95.
38. Morganti-Kossmann M.C., Satgunaseelan L., Bye N., Kossmann T. Modulation of immune response by head injury. Injury 2007, 38:1392-1400.
39. Chiaretti A., Antonelli A., Mastrangelo A., Pezzotti P., Tortorolo L., Tosi F., Genovese O. Interleukin-6 and nerve growth factor upregulation correlates with improved outcome in children with severe traumatic brain injury. J. Neurotrauma 2008, 25:225-234.
40. Winter C.D., Pringle A.K., Clough G.F., Church M.K. Raised parenchymal interleukin-6 levels correlate with improved outcome after traumatic brain injury. Brain 2004, 127:315-320.
41. Ishihara K., Hirano T. IL-6 in autoimmune disease and chronic inflammatory proliferative disease. Cytokine Growth Factor Rev. 2002, 13:357-368.
42. Bettelli E., Carrier Y., Gao W., Korn T., Strom T.B., Oukka M., Weiner H.L., Kuchroo V.K. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 2006, 441:235-238.
43. McGeachy M.J., Bak-Jensen K.S., Chen Y., Tato C.M., Blumenschein W., McClanahan T., Cua D.J. TGF-beta and IL-6 drive the production of IL-17 and IL-10 by T cells and restrain T(H)-17 cell-mediated pathology. Nat. Immunol. 2007, 8:1390-1397.
44. Veldhoen M., Hocking R.J., Atkins C.J., Locksley R.M., Stockinger B. TGFbeta in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells. Immunity 2006, 24:179-189.
45. + Th cells that cause autoimmune arthritis. J. Exp. Med. 2007, 204:41-47.
46. Mendel I., Katz A., Kozak N., Ben-Nun A., Revel M. Interleukin-6 functions in autoimmune encephalomyelitis: a study in gene-targeted mice. Eur. J. Immunol. 1998, 28:1727-1737.
47. Quintana A., Muller M., Frausto R.F., Ramos R., Getts D.R., Sanz E., Hofer M.J., Krauthausen M., King N.J., Hidalgo J., Campbell I.L. Site-specific production of IL-6 in the central nervous system retargets and enhances the inflammatory response in experimental autoimmune encephalomyelitis. J. Immunol. 2009, 183:2079-2088.
48. Ware C.F. The TNF superfamily-2008. Cytokine Growth Factor Rev. 2008, 19:183-186.
49. Kriegler M., Perez C., DeFay K., Albert I., Lu S.D. A novel form of TNF/cachectin is a cell surface cytotoxic transmembrane protein: ramifications for the complex physiology of TNF. Cell 1988, 53:45-53.
50. Perez C., Albert I., DeFay K., Zachariades N., Gooding L., Kriegler M. A nonsecretable cell surface mutant of tumor necrosis factor (TNF) kills by cell-to-cell contact. Cell 1990, 63:251-258.
51. McCoy M.K., Tansey M.G. TNF signaling inhibition in the CNS: implications for normal brain function and neurodegenerative disease. J. Neuroinflammation. 2008, 5:45.
52. Probert L., Akassoglou K., Pasparakis M., Kontogeorgos G., Kollias G. Spontaneous inflammatory demyelinating disease in transgenic mice showing central nervous system-specific expression of tumor necrosis factor α. Proc. Natl. Acad. Sci. U. S. A. 1995, 92:11294-11298.
53. Akassoglou K., Bauer J., Kassiotis G., Pasparakis M., Lassman H., Kollias G., Probert L. Oligodendrocyte apoptosis and primary demyelination induced by local TNF/p55TNF receptor signaling in the central nervous system of transgenic mice. Am. J. Pathol. 1998, 153:801-813.
54. Akassoglou K., Probert L., Kontogeorgos G., Kollias G. Astrocyte-specific but not neuron-specific transmembrane TNF triggers inflammation and degeneration in the central nervous system of transgenic mice. J. Immunol. 1997, 158:438-445.
55. Stalder A.K., Carson M.J., Pagenstecher A., Asensio V.C., Kincaid C., Benedict M., Powell H.C., Masliah E., Campbell I.L. Late-onset chronic inflammatory encephalopathy in immune-competent and severe combined immune-deficient (SCID) mice with astrocyte-targeted expression of tumor necrosis factor. Am. J. Pathol. 1998, 153:767-783.
56. Taupin V., Renno T., Bourbonniere L., Peterson A.C., Rodriguez M., Owens T. Increased severity of experimental autoimmune encephalomyelitis, chronic macrophage/microglial reactivity, demyelination in transgenic mice producing tumor necrosis factor-α in the central nervous system. Eur. J. Immunol. 1997, 27:905-913.
57. TNF receptor triggers inflammatory ischemia in the CNS of transgenic mice. Proc. Natl. Acad. Sci. U. S. A. 2003, 100:709-714.
58. Trinchieri G. Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat. Rev., Immunol. 2003, 3:133-146.
59. Park J.-H., Shin S.-H. Induction of IL-12 gene expression in the brain in septic shock. Biochem. Biophys. Res. 1996, 224:391-396.
60. Stalder A., Pagenstecher A., Yu N.C., Kincaid C., Chiang C.-S., Hobbs M.V., Bloom F.E., Campbell I.L. Lipopolysaccharide induced interleukin-12 expression in the CNS and cultured astrocytes and microglia. J. Immunol. 1997, 159:1344-1351.
61. Windhagen A., Newcombe J., Dangond F., Strand C., Woodroofe M.N., Cuzner M.L., Hafler D.A. Expression of costimulatory molecules B7-1 (CD80), B7-2 (CD86), and interleukin 12 cytokine in multiple sclerosis lesions. J. Exp. Med. 1995, 182:1986-1996.
62. Aloisi F., Penna G., Cerase J., Iglesias B., Adorini L. IL-12 production by central nervous system microglia is inhibited by astrocytes. J. Immunol. 1997, 159:1604-1612.
63. Constantinescu C.S., Frei K., Wysocka M., Trinchieri G., Malipiero U., Rostami A., Fontana A. Astrocytes and microglia produce interleukin-12 p40. Ann. N.Y. Acad. Sci. 1996, 795:328-333.
64. Becher B., Durell B.G., Noelle R.J. Experimental autoimmune encephalitis and inflammation in the absence of interleukin-12. J. Clin. Invest. 2002, 110:493-497.
65. Segal B.M., Constantinescu C.S., Raychaudhuri A., Kim L., Fidelus-Gort R., Kasper L.H. Repeated subcutaneous injections of IL12/23 p40 neutralising antibody, ustekinumab, in patients with relapsing-remitting multiple sclerosis: a phase II, double-blind, placebo-controlled, randomised, dose-ranging study. Lancet Neurol. 2008, 7:796-804.
66. Yap G., Pesin M., Sher A. Cutting edge: IL-12 is required for the maintenance of IFN-gamma production in T cells mediating chronic resistance to the intracellular pathogen, Toxoplasma gondii. J. Immunol. 2000, 165:628-631.
67. Pagenstecher A., Lassmann S., Carson M.J., Kincaid C.L., Stalder A.K., Campbell I.L. Astrocyte-targeted expression of IL-12 induces active cellular immune responses in the central nervous system and modulates experimental allergic encephalomyelitis. J. Immunol. 2000, 164:4481-4492.
68. Hofer M., Hausmann J., Staeheli P., Pagenstecher A. Cerebral expression of interleukin-12 induces neurological disease via differential pathways and recruits antigen-specific T cells in virus-infected mice. Am. J. Pathol. 2004, 165:949-958.
69. Lassmann S., Kincaid C., Asensio V.C., Campbell I.L. Induction of type I immune pathology in the brain following immunization without central nervous system autoantigen in transgenic mice with astrocyte-targeted expression of IL-12. J. Immunol. 2001, 167:5485-5493.
70. Hickey W.F., Hsu B.L., Kimura H. T-lymphocyte entry into the central nervous system. J. Neurosci. Res. 1991, 28:254-260.
71. Williams K.C., Hickey W.F. Traffic of hematogenous cells through the central nervous system. Curr. Topics Microbiol. Immunol. 1995, 202:221-245.
72. Rogge L., Barberis-Maino L., Biffi M., Passini N., Presky D.H., Gubler U., Sinigaglia F. Selective expression of an interleukin-12 receptor component by human T helper 1 cells. J. Exp. Med. 1997, 185:825-831.
73. Szabo S.J., Dighe A.S., Gubler U., Murphy K.M. Regulation of the interleukin (IL)-12Rb2 subunit expression in developing T helper 1 (Th1) and Th2 cells. J. Exp. Med. 1997, 185:817-824.
74. Panitch H.S. Influence of infection on exacerbations of multiple sclerosis. Ann. Neurol. 1994, 36:S25-S28.
75. Sibley W.A., Bamford C.R., Clark K. Clinical viral infections and multiple sclerosis. Lancet 1985, 1:1313-1315.
76. Tsunoda I., Tolley N.D., Theil D.J., Whitton J.L., Kobayashi H., Fujinami R.S. Exacerbation of viral and autoimmune animal models for multiple sclerosis by bacterial DNA. Brain Pathol. 1999, 9:481-493.
77. Murphy K.M., Murphy T.L., Szabo S.J., Jacobson N.G., Guler M.L., Gorham J.D., Gubler U. Regulation of IL-12 receptor expression in early T-helper responses implies two phases of Th1 differentiation: capacitance and development. Chem. Immunol. 1997, 68:54-69.
78. Maier J., Kincaid C., Pagenstecher A., Campbell I.L. Regulation of signal transducer and activator of transcription and suppressor of cytokine signaling gene expression in the brain of mice with astrocyte-targeted production of IL-12 and experimental autoimmune encephalomyelitis. Am. J. Pathol. 2002, 160:271-288.
79. Hilton D.J., Nicholson S.E. The SOCS proteins: a new family of negative regulators of signal transduction. J. Leukoc. Biol. 1998, 63:665-668.
80. Wang J., Campbel I.L. Cytokine signaling in the brain: putting a SOCS in it?. J. Neurosci. Res. 2002, 67:423-427.
81. de la Torre J.C. Borna virus and the brain. J. Infect. Dis. 2002, 186(Suppl. 2):S241-247.
82. Hallensleben W., Schwemmle M., Hausmann J., Stitz L., Volk B., Pagenstecher A., Staeheli P. Borna disease virus-induced neurological disorder in mice: infection of neonates results in immunopathology. J. Virol. 1998, 72:4379-4386.
83. Schamel K., Staeheli P., Hausmann J. Identification of the immunodominant H-2K(k)-restricted cytotoxic T-cell epitope in the Borna disease virus nucleoprotein. J. Virol. 2001, 75:8579-8588.
84. Freude S., Hausmann J., Hofer M., Pham-Mitchell N., Campbell I.L., Staeheli P., Pagenstecher A. Borna disease virus accelerates inflammation and disease associated with transgenic expression of interleukin-12 in the central nervous system. J. Virol. 2002, 76:12223-12232.
85. Friedl G., Hofer M., Auber B., Sauder C., Hausmann J., Staeheli P., Pagenstecher A. Borna disease virus multiplication in mouse organotypic slice cultures is site-specifically inhibited by gamma interferon but not by interleukin-12. J. Virol. 2004, 78:1212-1218.
86. + T cells and independently of interferon-γ. J. Neuropath. Exp. Neurol. 2009, 68:525-534.
87. Badn W., Visse E., Darabi A., Smith K.E., Salford L.G., Siesjo P. Postimmunization with IFN-gamma-secreting glioma cells combined with the inducible nitric oxide synthase inhibitor mercaptoethylguanidine prolongs survival of rats with intracerebral tumors. J. Immunol. 2007, 179:4231-4238.
88. Fathallah-Shaykh H.M., Zhao L.J., Kafrouni A.I., Smith G.M., Forman J. Gene transfer of IFN-gamma into established brain tumors represses growth by antiangiogenesis. J. Immunol. 2000, 164:217-222.
89. Kito T., Kuroda E., Yokota A., Yamashita U. Cytotoxicity in glioma cells due to interleukin-12 and interleukin-18-stimulated macrophages mediated by interferon-gamma-regulated nitric oxide. J. Neurosurg. 2003, 98:385-392.
90. Yu C.-R., Lin J.-X., Fink D.W., Akira S., Bloom E.T., Yamauchi A. Differential utilization of Janus kinase-signal transducer and activator of transcription signaling pathways in the stimulation of human natural killer cells by IL-2, IL-12, and IFN-α. J. Immunol. 1996, 157:126-137.
91. Wintterle S., Schreiner B., Mitsdoerffer M., Schneider D., Chen L., Meyermann R., Weller M., Wiendl H. Expression of the B7-related molecule B7-H1 by glioma cells: a potential mechanism of immune paralysis. Cancer Res. 2003, 63:7462-7467.
92. Pestka S., Krause C.D., Walter M.R. Interferons, interferon-like cytokines, and their receptors. Immunol. Rev. 2004, 202:8-32.
93. Sen G.C., Ransohoff R.M. Interferon-induced antiviral actions and their regulation. Adv. Virus Res. 1993, 42:57-102.
94. Jouanguy E., Zhang S.Y., Chapgier A., Sancho-Shimizu V., Puel A., Picard C., Boisson-Dupuis S., Abel L., Casanova J.L. Human primary immunodeficiencies of type I interferons. Biochimie 2007, 89:878-883.
95. Levin S., Hahn T. Interferon deficiency syndrome. Clin. Exp. Immunol. 1985, 60:267-273.
96. Muller U., Steinhoff U., Reis L.F.L., Hemmi S., Pavlovic J., Zinkernagel R.M., Aguet M. Functional role of type I and type II interferons in antiviral defense. Science 1994, 264:1918-1921.
97. van den Broek M.F., Muller U., Huang S., Aguet M., R.M.Z. Antiviral defense in mice lacking both alpha/beta and gamma interferon receptors. J. Virol. 1995, 69:4792-4796.
98. Boehm U., T.Klamp, Groot M., Howard J.C. Cellular responses to interferon-gamma. Ann. Rev. Immunol. 1997, 15:749-795.
99. Schroder K., Hertzog P.J., Ravasi T., Hume D.A. Interferon-gamma: an overview of signals, mechanisms and functions. J. Leukoc. Biol. 2004, 75:163-189.
100. Ank N., West H., Paludan S.R. IFN-lambda: novel antiviral cytokines. J. Interferon Cytokine Res. 2006, 26:373-379.
101. Schindler C., Strehlow I. Cytokines and STAT signaling. Adv. Pharmacol. 2000, 47:113-174.
102. Stark G.R., Kerr I.M., Williams B.R.G., Silverman R.H., Schreiber R.D. How cells respond to interferons. Ann. Rev. Biochem. 1998, 67:227-264.
103. Alsharifi M., Mullbacher A., Regner M. Interferon type I responses in primary and secondary infections. Immunol. Cell. Biol. 2008, 86:239-245.
104. Akiyama H., Ikeda K., Katoh M., McGeer E.G., McGeer P.L. Expression of MRP14, 27E10, interferon-α and leukocyte common antigen by reactive microglia in postmortem human brain tissue. J. Neuroimmunol. 1994, 50:195-201.
105. Lieberman A.P., Pitha P.M., Shin H.S., Shin M.L. Production of tumor necrosis factor and other cytokines by astrocytes stimulated with lipopolysaccharide or a neurotropic virus. Proc. Natl. Acad. Sci. U. S. A. 1989, 86:6348-6352.
106. de Veer M.J., Holko M., Frevel M., Walker E., Der S., Paranjape J.M., Silverman R.H., Williams R.G. Functional classification of interferon-stimulated genes identified using microarrays. J. Leukoc. Biol. 2001, 69:912-920.
107. Belardelli F., Gresser I. The neglected role of type 1 interferon in the T-cell response: implications for its clinical use. Immunol. Today 1996, 17:369-372.
108. Aicardi J., Goutieres F. A progressive familial encephalopathy in infancy with calcifications of the basal ganglia and chronic cerebrospinal fluid lymphocytosis. Ann. Neurol. 1984, 15:49-54.
109. Black D.N., Watters G.V., Andermann E., Dumont C., Kabay M.E., Kaplan P., Meagher-Villemure K., Michaud J., O'Gorman G., Reece E., Tsoukas C., Wainberg M.A. Encephalitis among Cree children in Northern Quebec. Ann. Neurol. 1988, 24:483-489.
110. Rho M.B., Wesselingh S., Glass J.D., McArthur J.C., Choi S., Griffin J., Tyor W.R. A potential role for interferon-α in the pathogenesis of HIV-associated dementia. Brain Behav. Immun. 1995, 9:366-377.
111. Dussaix E., Lebon P., Ponsot G., Huault G., Tardieu M. Intrathecal sythesis of different alpha-interferons in patients with various neurological diseases. Acta Neurol. Scand. 1985, 7:504-509.
112. Lebon P., Badoual J., Ponsot G., Goutieres F., Hemeury-Cukier F., Aicardi J. Intrathecal synthesis of interferon-alpha in infants with progressive familial encephalopathy. J. Neurol. Sci. 1988, 84:201-208.
113. Shiozawa S., Kuroki Y., Kim M., Hirohata S., Ogino T. Interferon-α in lupus psychosis. Arthritis Rheum. 1992, 35:417-422.
114. Winfield J.B., Shaw M., Silverman L.M., Eisenberg R.A., Wilson H.A., Koffler D. Intrathecal IgG synthesis and blood-brain barrier impairment in patients with systemic lupus erythematosus and central nervous system dysfunction. Am. J. Med. 1983, 74:837-844.
115. Gutterman J.U. Cytokine therapeutics: lessons from interferon α. Proc. Natl. Acad. Sci. USA 1994, 91:1198-1205.
116. Bocci V. Central nervous system toxicity of interferons and other cytokines. J. Biol. Regulators Homeostat. Agents 1988, 2:107-118.
117. Wichers M., Maes M. The psychoneuroimmuno-pathophysiology of cytokine-induced depression in humans. Int. J. Neuropsychopharmacol. 2002, 5:375-388.
118. Akwa Y., Hassett D.E., Eloranta M.L., Sandberg K., Masliah E., Powell H., Whitton J.L., Bloom F.E., Campbell I.L. Transgenic expression of IFN-α in the central nervous system of mice protects against lethal neurotropic viral infection but induces inflammation and neurodegeneration. J. Immunol. 1998, 161:5016-5026.
119. Campbell I.L., Krucker T., Steffensen S., Akwa Y., Powell H.C., Lane T., Carr D., Gold L.H., Henriksen S.J., Siggins G.R. Structural and functional neuropathology in transgenic mice with CNS expression of IFN-α. Brain Res. 1999, 835:46-61.
120. Kenneson A., Cannon M.J. Review and meta-analysis of the epidemiology of congenital cytomegalovirus (CMV) infection. Rev. Med. Virol. 2007, 17:253-276.
121. Price D.B., Inglese C.M., Jacobs J., Haller J.O., Kramer J., Hotson G.C., Loh J.P., Schlusselberg D., Menez-Bautista R., Rose A.L., et al. Pediatric AIDS. Neuroradiologic and neurodevelopmental findings. Pediatr. Radiol. 1988, 18:445-448.
122. Shaw D.W., Cohen W.A. Viral infections of the CNS in children: imaging features. AJR Am. J. Roentgenol. 1993, 160:125-133.
123. Brenneman D.E., McCune S.K., Mervis R.F., Hill J.M. gp120 as an etiologic agent for NeuroAIDS: neurotoxicity and model systems. Adv. Neuroimmunol. 1994, 4:157-165.
124. Belman A.L., Ultmann M.H., Horoupian D., Novick B., Spiro A.J., Rubinstein A., Kurtzberg D., Cone-Wesson B. Neurological complications in infants and children with acquired immune deficiency syndrome. Ann. Neurol. 1985, 18:560-566.
125. Aicardi J. Aicardi-Goutieres syndrome: special type early-onset encephalopathy. Eur. J. Paediatr. Neurol. 2002, 6(Suppl. A):A1-A7.
126. Kalil A.C., Devetten M.P., Singh S., Lesiak B., Poage D.P., Bargenquast K., Fayad P., Freifeld A.G. Use of interferon-alpha in patients with West Nile encephalitis: report of 2 cases. Clin. Infect. Dis. 2005, 40:764-766.
127. Huang S.S., Skolasky R.L., Dal Pan G.J., Royal W., McArthur J.C. Survival prolongation in HIV-associated progressive multifocal leukoencephalopathy treated with alpha-interferon: an observational study. J. Neurovirol. 1998, 4:324-332.
128. Steiger M.J., Tarnesby G., Gabe S., McLaughlin J., Schapira A.H. Successful outcome of progressive multifocal leukoencephalopathy with cytarabine and interferon. Ann. Neurol. 1993, 33:407-411.
129. Carr D.J., Veress L.A., Noisakran S., Campbell I.L. Astrocyte-targeted expression of IFN-alpha1 protects mice from acute ocular herpes simplex virus type 1 infection. J. Immunol. 1998, 161:4859-4865.
130. Staeheli P., Sentandreu M., Pagenstecher A., Hausmann J. Alpha/beta interferon promotes transcription and inhibits replication of Borna disease virus in persistently infected cells. J. Virol. 2001, 75:8216-8223.
131. van Boxel-Dezaire A.H., Rani M.R., Stark G.R. Complex modulation of cell type-specific signaling in response to type I interferons. Immunity 2006, 25:361-372.
132. Wang J., Schreiber R.D., Campbell I.L. STAT1 deficiency unexpectedly and markedly exacerbates the pathophysiological actions of IFN-α in the central nervous system. Proc. Natl. Acad. Sci. U. S. A. 2002, 99:16209-16214.
133. Wang J., Pham-Mitchell N., Schindler C., Campbell I.L. Dysregulated sonic hedgehog signaling and medulloblastoma consequent to IFN-α-stimulated STAT2-independent production of IFN-γ in the brain. J. Clin. Invest. 2003, 112:535-543.
134. Randall R.E., Goodbourn S. Interferons and viruses: an interplay between induction, signalling, antiviral responses and virus countermeasures. J. Gen. Virol. 2008, 89:1-47.
135. Crawford J.R., MacDonald T.J., Packer R.J. Medulloblastoma in childhood: new biological advances. Lancet Neurol. 2007, 6:1073-1085.
136. Ruiz i Altaba A., Sanchez P., Dahmane N. Gli and hedgehog in cancer: tumours, embryos and stem cells. Nat. Rev., Cancer 2002, 2:361-372.
137. Wechsler-Reya R., Scott M.P. The developmental biology of brain tumors. Ann. Rev. Neurosci. 2001, 24:385-428.
138. Chesler D.A., Reiss C.S. The role of IFN-gamma in immune responses to viral infections of the central nervous system. Cytokine Growth Factor Rev. 2002, 13:441-454.
139. Popko B., Corbin J.G., Baerwald K.D., Dupree J., Garcia A.M. The effects of interferon-gamma on the central nervous system. Mol. Neurobiol. 1997, 14:19-35.
140. Corbin J.G., Kelly D., Rath E.M., Baerwald K.D., Suzuki K., Popko B. Targeted CNS expression of interferon-g in transgenic mice leads to hypomyelination, reactive gliosis, and abnormal cerebellar development. Mol. Cell. Neurosci. 1996, 7:354-370.
141. Horwitz M.S., Evans C.F., McGavern D.B., Rodriguez M., Oldstone M.B.A. Primary demyelination in transgenic mice expressing IFN-γ. Nat. Med. 1997, 3:1037-1041.
142. LaFerla F.M., Sugarman M.C., Lane T.E., Leissring M.A. Regional hypomyelination and dysplasia in transgenic mice with astrocyte-targeted expression of interferon-γ. J. Mol. Neurosci. 2000, 15:45-59.
143. Balabanov R., Strand K., Kemper A., Lee J.Y., Popko B. Suppressor of cytokine signaling 1 expression protects oligodendrocytes from the deleterious effects of interferon-gamma. J. Neurosci. 2006, 26:5143-5152.
144. Baerwald K.D., Popko B. Developing and mature oligodendrocytes respond differently to the immune cytokine interferon-gamma. J. Neurosci. Res. 1998, 52:230-239.
145. Lin W., Harding H.P., Ron D., Popko B. Endoplasmic reticulum stress modulates the response of myelinating oligodendrocytes to the immune cytokine interferon-gamma. J. Cell Biol. 2005, 169:603-612.
146. Lin W., Popko B. Endoplasmic reticulum stress in disorders of myelinating cells. Nat. Neurosci. 2009, 12:379-385.
147. Lin W., Kemper A., Dupree J.L., Harding H.P., Ron D., Popko B. Interferon-gamma inhibits central nervous system remyelination through a process modulated by endoplasmic reticulum stress. Brain 2006, 129:1306-1318.
148. Renno T., Taupin V., Bourbonniere L., Verge G., Tran E., De Simone R., Krakowski M., Rodriguez M., Peterson A., Owens T. Interferon-γ in progression to chronic demyelination and neurological deficit following acute EAE. Mol. Cell. Neurosci. 1998, 12:376-389.
149. Balabanov R., Strand K., Goswami R., McMahon E., Begolka W., Miller S.D., Popko B. Interferon-gamma-oligodendrocyte interactions in the regulation of experimental autoimmune encephalomyelitis. J. Neurosci. 2007, 27:2013-2024.
150. Lin W., Bailey S.L., Ho H., Harding H.P., Ron D., Miller S.D., Popko B. The integrated stress response prevents demyelination by protecting oligodendrocytes against immune-mediated damage. J. Clin. Invest. 2007, 117:448-456.
151. Lin W., Kemper A., McCarthy K.D., Pytel P., Wang J., Campbell I.L., Utset M.F., Popko B. Interferon-γ-induced medulloblastoma in the developing cerebellum. J. Neurosci. 2004, 10:10074-10083.
152. Wang J., Lin W., Popko B., Campbel I.L. Inducible production of interferon-γ in the developing brain causes cerebellar dysplasia with the activation of the sonic hedgehog pathway. Mol. Cell. Neurosci. 2004, 27:489-496.
153. Derynck R., Akhurst R.J. Differentiation plasticity regulated by TGF-beta family proteins in development and disease. Nat. Cell. Biol. 2007, 9:1000-1004.
154. Li M.O., Flavell R.A. TGF-beta: a master of all T cell trades. Cell 2008, 134:392-404.
155. Massague J., Blain S.W., Lo R.S. TGFbeta signaling in growth control, cancer, and heritable disorders. Cell 2000, 103:295-309.
156. Derynck R., Zhang Y.E. Smad-dependent and Smad-independent pathways in TGF-beta family signalling. Nature 2003, 425:577-584.
157. Zhang Y.E. Non-Smad pathways in TGF-beta signaling. Cell Res. 2009, 19:128-139.
158. Finch C.E., Laping N.J., Morgan T.E., Nichols N.R., Pasinetti G.M. TGF-beta 1 is an organizer of responses to neurodegeneration. J. Cell. Biochem. 1993, 53:314-322.
159. Pratt B.M., McPherson J.M. TGF-beta in the central nervous system: potential roles in ischemic injury and neurodegenerative diseases. Cytokine Growth Factor Rev. 1997, 8:267-292.
160. 1 in the central nervous system of transgenic mice results in hydrocephalus. J. Neuropathol. Exp. Neurol. 1995, 54:339-349.
161. 1. Am. J. Pathol. 1995, 147:53-67.
162. Tada T., Kanaji M., Kobayashi S. Induction of communicating hydrocephalus in mice by intrathecal injection of human recombinant transforming growth factor-beta 1. J Neuroimmunol 1994, 50:153-158.
163. Kitazawa K., Tada T. Elevation of transforming growth factor-beta 1 level in cerebrospinal fluid of patients with communicating hydrocephalus after subarachnoid hemorrhage. Stroke 1994, 25:1400-1404.
164. Buckwalter M.S., Yamane M., Coleman B.S., Ormerod B.K., Chin J.T., Palmer T., Wyss-Coray T. Chronically increased transforming growth factor-beta1 strongly inhibits hippocampal neurogenesis in aged mice. Am. J. Pathol. 2006, 169:154-164.
165. Brionne T.C., Tesseur I., Masliah E., Wyss-Coray T. Loss of TGF-beta 1 leads to increased neuronal cell death and microgliosis in mouse brain. Neuron 2003, 40:1133-1145.
166. Boche D., Cunningham C., Gauldie J., Perry V.H. Transforming growth factor-beta 1-mediated neuroprotection against excitotoxic injury in vivo. J. Cereb. Blood Flow Metab. 2003, 23:1174-1182.
167. Pang L., Ye W., Che X.M., Roessler B.J., Betz A.L., Yang G.Y. Reduction of inflammatory response in the mouse brain with adenoviral-mediated transforming growth factor-ss1 expression. Stroke 2001, 32:544-552.
168. Prehn J.H., Bindokas V.P., Marcuccilli C.J., Krajewski S., Reed J.C., Miller R.J. Regulation of neuronal Bcl2 protein expression and calcium homeostasis by transforming growth factor type beta confers wide-ranging protection on rat hippocampal neurons. Proc. Natl. Acad. Sci. U. S. A. 1994, 91:12599-12603.
169. Zhu Y., Yang G.Y., Ahlemeyer B., Pang L., Che X.M., Culmsee C., Klumpp S., Krieglstein J. Transforming growth factor-beta 1 increases bad phosphorylation and protects neurons against damage. J. Neurosci. 2002, 22:3898-3909.
170. Krieglstein K., Farkas L., Unsicker K. TGF-beta regulates the survival of ciliary ganglionic neurons synergistically with ciliary neurotrophic factor and neurotrophins. J. Neurobiol. 1998, 37:563-572.
171. Wyss-Coray T., Lin C., Sanan D.A., Mucke L., Masliah E. Chronic overproduction of transforming growth factor-beta1 by astrocytes promotes Alzheimer's disease-like microvascular degeneration in transgenic mice. Am. J. Pathol. 2000, 156:139-150.
172. Gaertner R.F., Wyss-Coray T., Von Euw D., Lesne S., Vivien D., Lacombe P. Reduced brain tissue perfusion in TGF-beta 1 transgenic mice showing Alzheimer's disease-like cerebrovascular abnormalities. Neurobiol. Dis. 2005, 19:38-46.
173. Love S., Miners S., Palmer J., Chalmers K., Kehoe P. Insights into the pathogenesis and pathogenicity of cerebral amyloid angiopathy. Front. Biosci. 2009, 14:4778-4792.
174. Smith E.E., Greenberg S.M. beta-Amyloid, blood vessels, and brain function. Stroke 2009, 40:2601-2606.
175. Masliah E., Ho G., Wyss-Coray T. Functional role of TGF beta in Alzheimer's disease microvascular injury: lessons from transgenic mice. Neurochem. Int. 2001, 39:393-400.
176. Wyss-Coray T., Masliah E., Mallory M., McConologue L., Johnson-Wood K., Lin C., Mucke L. Amyloidogenic role of cytokine TGF-beta1 in transgenic mice and in Alzheimer's disease. Nature 1997, 389:603-606.
177. Tesseur I., Zou K., Esposito L., Bard F., Berber E., Can J.V., Lin A.H., Crews L., Tremblay P., Mathews P., Mucke L., Masliah E., Wyss-Coray T. Deficiency in neuronal TGF-beta signaling promotes neurodegeneration and Alzheimer's pathology. J. Clin. Invest. 2006, 116:3060-3069.
178. 1 promotes microglial amyloid-β clearance and reduces plaque burden in transgenic mice. Nat. Med. 2001, 7:612-618.
179. Wyss-Coray T., Yan F., Lin A.H., Lambris J.D., Alexander J.J., Quigg R.J., Masliah E. Prominent neurodegeneration and increased plaque formation in complement-inhibited Alzheimer's mice. Proc. Natl. Acad. Sci. U. S. A. 2002, 99:10837-10842.
180. Buckwalter M.S., Coleman B.S., Buttini M., Barbour R., Schenk D., Games D., Seubert P., Wyss-Coray T. Increased T cell recruitment to the CNS after amyloid beta 1-42 immunization in Alzheimer's mice overproducing transforming growth factor-beta 1. J. Neurosci. 2006, 26:11437-11441.
181. Luo J., Ho P.P., Buckwalter M.S., Hsu T., Lee L.Y., Zhang H., Kim D.K., Kim S.J., Gambhir S.S., Steinman L., Wyss-Coray T. Glia-dependent TGF-beta signaling, acting independently of the TH17 pathway, is critical for initiation of murine autoimmune encephalomyelitis. J. Clin. Invest. 2007, 117:3306-3315.
182. 1 enhances inflammatory central nervous system disease in transgenic mice. J. Neuroimmunol. 1997, 77:45-50.
183. De Groot C.J., Montagne L., Barten A.D., Sminia P., Van Der Valk P. Expression of transforming growth factor (TGF)-beta1, -beta2, and -beta3 isoforms and TGF-beta type I and type II receptors in multiple sclerosis lesions and human adult astrocyte cultures. J. Neuropathol. Exp. Neurol. 1999, 58:174-187.
184. Kuruvilla A.P., Shah R., Hochwald G.M., Liggitt H.D., Palladino M.A., Thorbecke G.J. Protective effect of transforming growth factor beta 1 on experimental autoimmune diseases in mice. Proc. Natl. Acad. Sci. U. S. A. 1991, 88:2918-2921.
185. Racke M.K., Dhib-Jalbut S., Cannella B., Albert P.S., Raine C.S., McFarlin D.E. Prevention and treatment of chronic relapsing experimental allergic encephalomyelitis by transforming growth factor-beta 1. J. Immunol. 1991, 146:3012-3017.
186. Santambrogio L., Hochwald G.M., Saxena B., Leu C.H., Martz J.E., Carlino J.A., Ruddle N.H., Palladino M.A., Gold L.I., Thorbecke G.J. Studies on the mechanisms by which transforming growth factor-beta (TGF-beta) protects against allergic encephalomyelitis. Antagonism between TGF-beta and tumor necrosis factor. J. Immunol. 1993, 151:1116-1127.